Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Renal Insufficiency, Chronic 1Non-alcoholic Fatty Liver Disease 1Liver Cirrhosis, Alcoholic 1Hypothermia 1Hepatitis C 1Hepatitis B 1Fibrosis 1End Stage Liver Disease 1Carcinoma, Hepatocellular 1Acute Kidney Injury 1

Interventions

Sorafenib 29Nivolumab 15pembrolizumab 12Radiosurgery 9Bevacizumab 9atezolizumab 7regorafenib 5Radiotherapy 5Fluorouracil 5Doxorubicin 5lenvatinib 4Sunitinib 4Oxaliplatin 4Ipilimumab 4Gemcitabine 4Ethiodized Oil 4Erlotinib Hydrochloride 4Capecitabine 4TLC 388 3Radiofrequency Ablation 3Leucovorin 3Everolimus 3Cisplatin 3Blood Specimen Collection 3toripalimab 2phosphomannopentaose sulfate 2durvalumab 2cediranib 2avelumab 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Hepatocellular × Hypothermia, Induced × Clear all
NCT03534141 2025-05-16

MHALT

University of California, San Francisco

Phase NA Terminated
175 enrolled 19 charts
GastrointestinalGenitourinary

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Hypothermia, Liver Cirrhosis, Alcoholic, Renal Insufficiency, Chronic, Acute Kidney Injury, End Stage Liver Disease, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡